Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Animal Models

α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3

International Journal of Obesity volume 43, pages 202–216 (2019)Cite this article

Subjects

Abstract

Objective

The increasing global prevalence of obesity and its associated disorders points to an urgent need for the development of novel and effective strategies for the prevention of weight gain. Here, we investigated the potential of α-cedrene, a volatile sesquiterpene compound derived from cedarwood oil, in regulation of obesity and delineated the mechanisms involved.

Methods

For the prevention of obesity, C57BL/6 N mice were fed a high-fat diet (HFD) and were orally administered either with vehicle or α-cedrene for 8 weeks. For the therapy of obesity, obese Sprague Dawley rats, induced by a HFD for 8 weeks, were orally treated either with vehicle or α-cedrene for 12 weeks. To determine whether the action of α-cedrene was Adcy3 dependent, Adcy3 heterozygous null mice (Adcy3+/−) and wild-type controls were fed either HFD or α-cedrene supplemented HFD for 17 weeks.

Results

Oral α-cedrene administration prevented or reversed HFD-induced obesity and abnormal metabolic aberrations in rodents, without affecting their food intake. Downregulation of Adcy3 expression by small interfering RNA abrogated the beneficial effects of α-cedrene on the oxygen consumption rate and intracellular lipid accumulation in 3T3-L1 adipocytes. Similarly, in Adcy3+/− mice, the α-cedrene-driven suppression of body weight gain observed in wild-type mice was substantially (~50%) attenuated. Expression of thermogenic and lipid oxidation genes was increased in adipose tissues of α-cedrene-treated mice, with concomitant downregulation of adipogenic gene expression. These beneficial molecular changes elicited by α-cedrene were blunted in adipose tissues of Adcy3+/− mice.

Conclusions

Our results highlight the potential of α-cedrene for antiobesity interventions and suggest that the antiobesity effect of α-cedrene is mediated by Adcy3 in adipose tissues.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Crowley VE, Yeo GS, O’Rahilly S. Obesity therapy: altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Discov. 2002;1:276–86.

    Article  CAS  Google Scholar 

  2. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014;220:T47–59.

    Article  CAS  Google Scholar 

  3. Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197–209.

    Article  Google Scholar 

  4. Jackson VM, Breen DM, Fortin JP, Liou A, Kuzmiski JB, Loomis AK, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Dis. 2015;10:825–39.

    Article  CAS  Google Scholar 

  5. Barja-Fernandez S, Leis R, Casanueva FF, Seoane LM. Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss. Drug Des Dev Ther. 2014;8:2391–2400.

    CAS  Google Scholar 

  6. Jackson VM, Price DA, Carpino PA. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig. Drugs. 2014;23:1055–66.

    Article  CAS  Google Scholar 

  7. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today. 2013;18:1067–73.

    Article  CAS  Google Scholar 

  8. Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther. 2013;93:299–301.

    Article  CAS  Google Scholar 

  9. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–19.

    Article  CAS  Google Scholar 

  10. Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin MJ, et al. Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 2012;16:765–76.

    Article  CAS  Google Scholar 

  11. Rogne M, Tasken K. Compartmentalization of cAMP signaling in adipogenesis, lipogenesis, and lipolysis. Horm Metab Res. 2014;46:833–40.

    Article  CAS  Google Scholar 

  12. Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal. 2006;18:401–8.

    Article  CAS  Google Scholar 

  13. Madsen L, Kristiansen K. The importance of dietary modulation of cAMP and insulin signaling in adipose tissue and the development of obesity. Ann N Y Acad Sci. 2010;1190:1–14.

    Article  CAS  Google Scholar 

  14. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19:1252–63.

    Article  CAS  Google Scholar 

  15. Yin W, Mu J, Birnbaum MJ. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. J Biol Chem. 2003;278:43074–80.

    Article  CAS  Google Scholar 

  16. Omar B, Zmuda-Trzebiatowska E, Manganiello V, Goransson O, Degerman E. Regulation of AMP-activated protein kinase by cAMP in adipocytes: Roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal. 2009;21:760–6.

    Article  CAS  Google Scholar 

  17. Qiu L, LeBel RP, Storm DR, Chen X. Type 3 adenylyl cyclase: a key enzyme mediating the cAMP signaling in neuronal cilia. Int J Physiol Pathophysiol Pharmacol. 2016;8:95–108.

    PubMed  PubMed Central  CAS  Google Scholar 

  18. Cooper DMF. Regulation and organization of adenylyl cyclases and cAMP. Biochem J. 2003;375:517–29.

    Article  CAS  Google Scholar 

  19. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol. 2001;41:145–74.

    Article  CAS  Google Scholar 

  20. Pierre S, Eschenhagen T, Geisslinger G, Scholich K. Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov. 2009;8:321–35.

    Article  CAS  Google Scholar 

  21. Pavan B, Biondi C, Dalpiaz A. Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today. 2009;14:982–91.

    Article  CAS  Google Scholar 

  22. Nordman S, Abulaiti A, Hilding A, Langberg EC, Humphreys K, Ostenson CG, et al. Genetic variation of the adenylyl cyclase 3 (AC3) locus and its influence on type 2 diabetes and obesity susceptibility in Swedish men. Int J Obes (Lond). 2008;32:407–12.

    Article  CAS  Google Scholar 

  23. Wang HR, Wu M, Zhu WG, Shen J, Shi XM, Yang J et al. Evaluation of the association between the AC3 genetic polymorphisms and obesity in a chinese Han population. PLoS ONE. 2010;5:e13851.

    Article  CAS  Google Scholar 

  24. Wu L, Shen C, Ahmed MS, Ostenson CG, Gu HF. Adenylate cyclase 3: a new target for anti-obesity drug development. Obes Rev. 2016;17:907–14.

    Article  CAS  Google Scholar 

  25. The right form for ref. 25 is:Pitman JL, Wheeler MC, Lloyd DJ, Walker JR, Glynne RJ, Gekakis N. A gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesity. PLoS ONE. 2014;9:e110226.

    Article  CAS  Google Scholar 

  26. Tong T, Shen Y, Lee HW, Yu R, Park T. Adenylyl cyclase 3 haploinsufficiency confers susceptibility to diet-induced obesity and insulin resistance in mice. Sci Rep. 2016;6:34179.

    Article  CAS  Google Scholar 

  27. Liang Y, Li Z, Liang S, Li Y, Yang L, Lu M, et al. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity. Nutr Diabetes. 2016;6:e191.

    Article  CAS  Google Scholar 

  28. Li Z, Liang Y, Xia N, Lai Y, Pan H, Zhou S, et al. Liraglutide reduces body weight by upregulation of adenylate cyclase 3. Nutr Diabetes. 2017;7:e265.

    Article  CAS  Google Scholar 

  29. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.

    Article  CAS  Google Scholar 

  30. Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, et al. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity. 2008;16:1510–5.

    Article  CAS  Google Scholar 

  31. Shen Y, Song SJ, Keum N, Park T. Olive leaf extract attenuates obesity in high-fat diet-fed mice by modulating the expression of molecules involved in adipogenesis and thermogenesis. Evid Based Complement Alternat Med. 2014;2014:971890.

    PubMed  PubMed Central  Google Scholar 

  32. Kym PR, Iyengar R, Souers AJ, Lynch JK, Judd AS, Gao J, et al. Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J Med Chem. 2005;48:5888–91.

    Article  CAS  Google Scholar 

  33. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology. 2012;63:132–46.

    Article  CAS  Google Scholar 

  34. Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AMD, Raben A, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010;636:88–95.

    Article  CAS  Google Scholar 

  35. Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. 2007;15:798–808.

    Article  CAS  Google Scholar 

  36. Forgacs AL, Kent MN, Makley MK, Mets B, DelRaso N, Jahns GL, et al. Comparative metabolomic and genomic analyses of TCDD-elicited metabolic disruption in mouse and rat liver. Toxicol Sci. 2012;125:41–55.

    Article  CAS  Google Scholar 

  37. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44.

    PubMed  CAS  Google Scholar 

  38. Kim TH, Yoo SD, Lee HS, Lee KM, Seok SH, Kim MG, et al. In vivo absorption and disposition of alpha-cedrene, a sesquiterpene constituent of cedarwood oil, in female and male rats. Drug Metab Pharmacokinet. 2015;30:168–73.

    Article  CAS  Google Scholar 

  39. Livera G, Xie F, Garcia MA, Jaiswal B, Chen J, Law E, et al. Inactivation of the mouse adenylyl cyclase 3 gene disrupts male fertility and spermatozoon function. Mol Endocrinol. 2005;19:1277–90.

    Article  CAS  Google Scholar 

  40. Wong ST, Trinh K, Hacker B, Chan GCK, Lowe G, Gaggar A, et al. Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice. Neuron. 2000;27:487–97.

    Article  CAS  Google Scholar 

  41. Pluznick JL, Zou DJ, Zhang XH, Yan QS, Rodriguez-Gil DJ, Eisner C, et al. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA. 2009;106:2059–64.

    Article  Google Scholar 

  42. Dodge-Kafka KL, Bauman A, Mayer N, Henson E, Heredia L, Ahn J, et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring Protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078–86.

    Article  CAS  Google Scholar 

  43. Taylor SS, Kim C, Cheng CY, Brown SHJ, Wu H, Kannan N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. BBA Proteins Proteom. 2008;1784:16–26.

    Article  CAS  Google Scholar 

  44. Habinowski SA, Witters LA. The effects of AICAR on adipocyte differentiation of 3T3-L1 cells. Biochem Biophys Res Commun. 2001;286:852–6.

    Article  CAS  Google Scholar 

  45. Rosen ED, Spiegelman BM. PPAR gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731–4.

    Article  CAS  Google Scholar 

  46. Catania C, Binder E, Cota D. mTORC1 signaling in energy balance and metabolic disease. Int J Obes. 2011;35:751–61.

    Article  CAS  Google Scholar 

  47. Inoki K, Zhu TQ, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90.

    Article  CAS  Google Scholar 

  48. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system - from concept to molecular analysis. Eur J Biochem. 1997;244:1–14.

    Article  CAS  Google Scholar 

  49. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest. 2011;121:2102–10.

    Article  CAS  Google Scholar 

  50. Cao WH, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol. 2004;24:3057–67.

    Article  CAS  Google Scholar 

  51. Tong T, Ryu SE, Min Y, de March CA, Bushdid C, Golebiowski J, et al. Olfactory receptor 10J5 responding to alpha-cedrene regulates hepatic steatosis via the cAMP-PKA pathway. Sci Rep. 2017;7:9471.

    Article  CAS  Google Scholar 

  52. Kim SH, Yoon YC, Hwang JT, Sung MJ, Kim MS, Hur HJ, et al. Tangeretin synergistically enhances odorant-induced increases in cAMP and calcium levels and CREB phosphorylation in non-neuronal 3T3-L1 cells. Appl Biol Chem. 2016;59:103–8.

    Article  CAS  Google Scholar 

  53. Choi Y, Hur CG, Park T. Induction of olfaction and cancer-related genes in mice fed a high-fat diet as assessed through the mode-of-action by network identification analysis. PLoS ONE. 2013;8:e56610.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Research Foundation of Korea Grant (funded by the Korean Government; NRF-2016R1A2B4016189) and the grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2243).

Author contributions

TT and TP designed the study; TT and TP conducted the experiments; TT analyzed the data; TT, RY, and TP wrote the manuscript.

Author information

Authors and Affiliations

  1. Department of Food and Nutrition, Brain Korea 21 PLUS Project, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, South Korea

    Tao Tong & Taesun Park

  2. Department of Food Science and Nutrition, University of Ulsan, Mugeo-dong, Nam-ku, Ulsan, 680-749, South Korea

    Rina Yu

Authors
  1. Tao Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rina Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taesun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taesun Park.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tong, T., Yu, R. & Park, T. α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3. Int J Obes 43, 202–216 (2019). https://doi.org/10.1038/s41366-018-0176-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41366-018-0176-0

Search

Advanced search

Quick links